Chernett Jorey
Reporting owner on Forms 3, 4 and 5, CIK 2042077.
Chernett Jorey reported on 3 issuers in 18 filings, the latest a 13D/A filed 2026-11-19.
Issuers
| Issuer | Roles in the latest filing | Filings | Last filed |
|---|---|---|---|
| STIM · Neuronetics, Inc.CIK 1227636 | 10% owner | 2 | 2026-11-13 |
| XGN · EXAGEN INC.CIK 1274737 | 10% owner | 5 | 2026-11-13 |
| Starling Oncology, Inc. CIK 1799191 | 10% owner | 3 | 2026-11-13 |
Transactions and holdings
Every row of the person's Forms 3, 4 and 5, newest first, with the price and the amount owned after the row as filed.
| Security | Date | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| STIM · Neuronetics, Inc.Common Stock | 2026-11-13 | S sold | -2,187,051 | $1.15 | 7,325,577 | Form 4 |
| XGN · EXAGEN INC.Common Stock | 2026-11-13 | S sold | -58,068 | $4.08 | 2,529,436 | Form 4 |
| STIM · Neuronetics, Inc.Common Stock | 2026-11-12 | S sold | -706,840 | $1.43 | 9,512,628 | Form 4 |
| XGN · EXAGEN INC.Common Stock | 2026-11-12 | S sold | -109,436 | $4.65 | 2,587,504 | Form 4 |
| STIM · Neuronetics, Inc.Common Stock | 2026-11-11 | S sold | -86,757 | $1.61 | 10,219,468 | Form 4 |
| STLN · Starling Oncology, Inc.Call Option (STLN 19FEB27 $4C), derivative | 2026-11-11 | P bought | +1,391 | $0.8 | 6,391 | Form 4/A |
| XGN · EXAGEN INC.Common Stock | 2026-11-11 | P bought | +71,315 | $5.23 | 2,696,940 | Form 4 |
| STLN · Starling Oncology, Inc.Call Option (STLN 19FEB27 $4C), derivative, superseded by an amendment | 2026-11-11 | P bought | +1,391 | $0.8 | 6,391 | Form 4 |
| XGN · EXAGEN INC.Common Stock | 2026-11-10 | P bought | +7,085 | $5.26 | 2,625,625 | Form 4 |
| STLN · Starling Oncology, Inc.Call Option (STLN 21MAY27 $5C), derivative | 2026-11-10 | P bought | +7,000 | $0.67 | 7,000 | Form 4 |
| STIM · Neuronetics, Inc.Common Stock | 2026-11-09 | S sold | -103,959 | $2.06 | 10,266,225 | Form 4 |
| STIM · Neuronetics, Inc.Common Stock | 2026-11-09 | P bought | +40,000 | $1.99 | 10,306,225 | Form 4 |
| XGN · EXAGEN INC.Common Stock | 2026-11-09 | P bought | +8,500 | $6.35 | 2,618,540 | Form 4 |
| STLN · Starling Oncology, Inc.Common Stock | 2026-11-09 | P bought | +48,294 | $3.65 | 7,858,091 | Form 4 |
| STLN · Starling Oncology, Inc.Call Option (STLN 19FEB27 $5C), derivative | 2026-11-09 | P bought | +7,500 | $0.5357 | 7,500 | Form 4 |
| STIM · Neuronetics, Inc.Common Stock | 2026-11-06 | S sold | -250,804 | $2.39 | 10,370,184 | Form 4 |
| XGN · EXAGEN INC.Common Stock | 2026-11-06 | S sold | -11,265 | $6.14 | 2,610,040 | Form 4 |
| STLN · Starling Oncology, Inc.Common Stock | 2026-11-06 | S sold | -2,851,061 | $3.99 | 7,809,797 | Form 4 |
| STLN · Starling Oncology, Inc.Call Option (STLN 20NOV26 $4C), derivative | 2026-11-06 | P bought | +10,000 | $0.075 | 10,000 | Form 4 |
| STLN · Starling Oncology, Inc.Call Option (STLN 19FEB27 $4C), derivative | 2026-11-06 | P bought | +5,000 | $0.4 | 5,000 | Form 4 |
| STIM · Neuronetics, Inc.Common Stock | 2026-10-30 | P bought | +18,000 | $2.27 | 10,620,988 | Form 4 |
| XGN · EXAGEN INC.Common Stock | 2026-10-19 | P bought | +14,000 | $7.46 | 2,618,540 | Form 4 |
| XGN · EXAGEN INC.Common Stock, holding | 2,604,540 | Form 3 |
Filings
The person's Forms 3, 4 and 5, and any 13D or 13G naming it.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13D/A 0000921895-26-003225 | SMHI | 2026-11-19 | ||
| 13G/A 0000921895-26-003192 | TRAW | 2026-11-16 | ||
| 13G/A 0000921895-26-003190 | Axonics | 2026-11-16 | ||
| 13G/A 0000921895-26-003188 | FEMY | 2026-11-16 | ||
| 13D/A 0001193805-26-001478 | STIM | 2026-11-16 | ||
| 13G/A 0001193805-26-001476 | XGN | 2026-11-13 | ||
| 13G/A 0001193805-26-001475 | XGN | 2026-11-13 | ||
| Form 4 0001193805-26-001472 | Neuronetics, Inc. | 2026-11-13 | ||
| Form 4 0001193805-26-001471 | EXAGEN INC. | 2026-11-13 | ||
| Form 4/A 0001193805-26-001470 | Starling Oncology, Inc. | 2026-11-13 | ||
| Form 4 0001193805-26-001456 | EXAGEN INC. | 2026-11-12 | ||
| Form 4 0001193805-26-001455 | Starling Oncology, Inc. | 2026-11-12 | ||
| Form 4 0000921895-26-003021 | EXAGEN INC. | 2026-11-10 | ||
| Form 4 0000921895-26-003018 | Starling Oncology, Inc. | 2026-11-10 | ||
| Form 4 0000921895-26-002891 | Neuronetics, Inc. | 2026-11-02 | ||
| Form 4 0001193805-26-001382 | EXAGEN INC. | 2026-10-20 | ||
| Form 3 0001193805-26-001378 | EXAGEN INC. | 2026-10-19 | ||
| 13D/A 0001193805-26-001332 | CVRX | 2026-10-02 |